A Covid-19 Patient with Complement-Mediated Coagulopathy and Severe Thrombosis

Showers, Christopher; Nuovo, Gerard J.; Lakhanpal, Amit; Siegel, Caroline H.; Aizer, Juliet; Elreda, Lauren; A, Halevi; Lai, Andrew; Erkan, Doruk; Magro, Cynthia M.

doi:10.1159/000512503

Cited by 16 publications

(13 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bennardo et al Studied Tocilizumab, which is a humanized receptor for interleukin-6 (IL-6R), a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling, used as a treatment for rheumatoid arthritis causing osteomyelitis of the jaw [ 25 , 26 ]. Considering the rheumatic treatment of patients with severe COVID-19 due to high CRP, we can see that this is close to the truth because there are cases of osteomyelitis, necrosis of other bones in the literature [ 27 , 28 ].…”

Section: Discussionsupporting

confidence: 63%

Complications of COVID-19 in the maxillo-facial region: Clinical case and review of the literature

Boymuradov

Rustamova

Bobamuratova

et al. 2021

Advances in Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

COVID-19 is currently causing a pandemic around the world. With the increase in the number of patients, there was a slight increase in the incidence of various complications. In particular, infectious and inflammatory diseases of the face and jaw are observed in patients with COVID-19 in the early infectious stages of the disease, as well as in the late stages. In the previous literature, as a sign or complication of COVID-19 were mentioned cases of changes in the oral cavity - ulcers, rashes, and inflammation of salivary glands. The conditions presented in this article are a serious complication of COVID-19, radically different from the usual course of osteomyelitis, in which the patient has a course with a predominance of long-term, chronic-progressive, atrophic processes. Treatment was somewhat ineffective due to local chronic inflammation (pansinusitis), metabolic, microcirculatory, immune, and coagulation disorders in patients.

show abstract

Section: Discussionsupporting

confidence: 63%

Complications of COVID-19 in the maxillo-facial region: Clinical case and review of the literature

Boymuradov

Rustamova

Bobamuratova

et al. 2021

Advances in Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

show abstract

“… 20 28 41 42 Complement activation has been well reported in patients with COVID-19, but its root causes remain to be properly delineated. 43–45 …”

Section: Discussionmentioning

confidence: 99%

Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review

et al. 2021

View full text Add to dashboard Cite

Although primarily affecting the respiratory system, COVID-19 causes multiple organ damage. One of its grave consequences is a prothrombotic state that manifests as thrombotic, microthrombotic and thromboembolic events. Therefore, understanding the effect of antiplatelet and anticoagulation therapy in the context of COVID-19 treatment is important. The aim of this rapid review was to highlight the role of thrombosis in COVID-19 and to provide new insights on the use of antithrombotic therapy in its management. A rapid systematic review was performed using preferred reporting items for systematic reviews. Papers published in English on antithrombotic agent use and COVID-19 complications were eligible. Results showed that the use of anticoagulants increased survival and reduced thromboembolic events in patients. However, despite the use of anticoagulants, patients still suffered thrombotic events likely due to heparin resistance. Data on antiplatelet use in combination with anticoagulants in the setting of COVID-19 are quite scarce. Current side effects of anticoagulation therapy emphasise the need to update treatment guidelines. In this rapid review, we address a possible modulatory role of antiplatelet and anticoagulant combination against COVID-19 pathogenesis. This combination may be an effective form of adjuvant therapy against COVID-19 infection. However, further studies are needed to elucidate potential risks and benefits associated with this combination.

show abstract

“…[19,27,39,40] Complement activation has been well reported in COVID-19 patients, but its root causes remain to be properly delineated. [41–43]…”

Section: Discussionmentioning

confidence: 99%

Role of Combining Anticoagulant and Antiplatelet Agents in COVID-19 Treatment: A Rapid Review

Matli

Farah

Maalouf

et al. 2021

Preprint

View full text Add to dashboard Cite

Although primarily affecting the respiratory system, COVID-19 causes multiple organ damage. One of its grave consequences is a prothrombotic state that manifests as thrombotic, microthrombotic, and thromboembolic events.Therefore, understanding the effect of antiplatelet and anticoagulation therapy in the context of COVID-19 treatment is important. The aim of this rapid review is to highlight the role of thrombosis in COVID-19 and provide new insights on the use of antithrombotic therapy in its management. A rapid systematic review was performed using preferred reporting items for systematic reviews. Papers published in English on antithrombotic agent use and COVID-19 complications were eligible. Results showed that the use of anticoagulants increased survival and reduced thromboembolic events in patients. However, despite the use of anticoagulants, patients still suffered thrombotic events likely due to heparin resistance. Data on antiplatelet use in combination with anticoagulants in the setting of COVID-19 is quite scarce. Current side effects of anticoagulation therapy emphasize the need to update treatment guidelines. In this rapid review, we address a possible modulatory role of antiplatelet and anticoagulant combination against COVID‐19 pathogenesis. This combination may be an effective form of adjuvant therapy against COVID‐19 infection. However, further studies are needed to elucidate potential risks and benefits associated with this combination.

show abstract

A Covid-19 Patient with Complement-Mediated Coagulopathy and Severe Thrombosis

Cited by 16 publications

References 49 publications

Complications of COVID-19 in the maxillo-facial region: Clinical case and review of the literature

Complications of COVID-19 in the maxillo-facial region: Clinical case and review of the literature

Role of combining anticoagulant and antiplatelet agents in COVID-19 treatment: a rapid review

Role of Combining Anticoagulant and Antiplatelet Agents in COVID-19 Treatment: A Rapid Review

Contact Info

Product

Resources

About